ReviewDermatology research and practice2014
Type I interferons: key players in normal skin and select cutaneous malignancies.
Review in Dermatology research and practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Immunotherapy in Basal Cell Carcinoma.Journal of clinical medicine · 2024Review
- Clinical features and prognosis of conjunctival melanoma in Japanese patients.Japanese journal of ophthalmology · 2024Observational
- The Immunotherapeutic Role of Type I and III Interferons in Melanoma and Non-Melanoma Skin Cancers.Life (Basel, Switzerland) · 2023Review
- Zika Virus from the Perspective of Observational Studies: a Review.Journal of arthropod-borne diseases · 2022Review
- Type I Interferons Enhance the Repair of Ultraviolet Radiation-Induced DNA Damage and Regulate Cutaneous Immune Suppression.International journal of molecular sciences · 2022Article
- Article
- Impact of Interferon-alpha1b (IFN-α1b) on Antitumor Immune Response: An Interpretation of the Promising Therapeutic Effect of IFN-alpha1b on Melanoma.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- A Novel Type-I Interferon Family, Bovine Interferon-Chi, Is Involved in Positive-Feedback Regulation of Interferon Production.Frontiers in immunology · 2020Article
- Sustained Regression of Hydroxycarbamide Induced Actinic Keratoses after Switching to Anagrelide.Case reports in dermatological medicine · 2018Article
- Transcription factors and stress response gene alterations in human keratinocytes following Solar Simulated Ultra Violet Radiation.Scientific reports · 2017Article
- Type I IFN family members: similarity, differences and interaction.Cytokine & growth factor reviews · 2015Review
- Novel anti-melanoma treatment: focus on immunotherapy.Chinese journal of cancer · 2014Article
- Interferons: Success in anti-viral immunotherapy.Cytokine & growth factor reviews · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferons (IFNs) are a family of naturally existing glycoproteins known for their antiviral activity and their ability to influence the behavior of normal and transformed cell types. Type I Interferons include IFN- α and IFN- β . Currently, IFN- α has numerous approved antitumor applications, including malignant melanoma, in which IFN- α has been shown to increase relapse free survival. Moreover, IFN- α has been successfully used in the intralesional treatment of cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). In spite of these promising clinical results; however, there exists a paucity of knowledge on the precise anti-tumor action of IFN- α / β at the cellular and molecular levels in cutaneous malignancies such as SCC, BCC, and melanoma. This review summarizes current knowledge on the extent to which Type I IFN influences proliferation, apoptosis, angiogenesis, and immune function in normal skin, cutaneous SCC, BCC, and melanoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.